Analyst Reco. Bioventus Inc.

Equities

BVS

US09075A1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-11 pm EDT			5-day change	1st Jan Change
6.53 ^USD	+0.93%		-2.54%	+23.91%

May. 07	Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024	CI
May. 07	Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating	Mar. 13	MT
Canaccord Genuity Upgrades Bioventus to Buy From Hold, Adjusts Price Target to $7 From $3.66	Dec. 07	MT
Craig-Hallum Adjusts Price Target on Bioventus to $5 From $10, Maintains Hold Rating	23-04-03	MT
Goldman Sachs Cuts Price Target on Bioventus to $2.50 From $13, Maintains Neutral Rating	22-11-30	MT
Craig-Hallum Downgrades Bioventus to Hold From Buy	22-11-22	MT
Morgan Stanley Adjusts Price Target on Bioventus to $5 From $11, Maintains Overweight Rating	22-11-10	MT
Canaccord Genuity Downgrades Bioventus to Hold From Buy, Adjusts Price Target to $6 From $18	22-11-09	MT
JPMorgan Downgrades Bioventus to Underweight From Overweight	22-11-09	MT
Morgan Stanley Adjusts Bioventus' Price Target to $11 From $12, Reiterates Overweight Rating	22-10-11	MT
Goldman Sachs Adjusts Bioventus' Price Target to $13 from $15, Maintains Neutral Rating	22-09-07	MT
Morgan Stanley Raises Bioventus' Price Target to $12 From $11, Maintains Overweight Rating	22-08-12	MT
Morgan Stanley Lowers Bioventus Price Target to $11 From $18, Maintains Overweight Rating	22-05-12	MT
Goldman Sachs Adjusts Bioventus Price Target to $17 From $19, Maintains Neutral Rating	22-03-21	MT
Craig-Hallum Starts Bioventus at Buy with $30 Price Target	22-03-15	MT
Morgan Stanley Resumes Bioventus at Overweight With $20 Price Target	21-11-15	MT
JPMorgan Reinstates Bioventus at Overweight With $25 Price Target	21-11-10	MT
BIOVENTUS : Goldman Sachs Cuts Bioventus to Neutral From Buy, Price Target to $19 From $20	21-07-01	MT
BIOVENTUS : Morgan Stanley Adjusts Price Target on Bioventus to $19 From $18, Maintains Overweight Rating	21-04-19	MT
BIOVENTUS : Morgan Stanley Starts Bioventus at Overweight With $18 Price Target	21-03-08	MT
BIOVENTUS : JPMorgan Initiates Bioventus at Overweight With $17 Price Target	21-03-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Bioventus Inc.

Equities

BVS

US09075A1088

Analyst Reco.

Filters